RIGEL PHARMACEUTICALS INC— Sankey Diagram

Quarterly mode · period ending 2026-03-31 · SEC EDGAR

ComparingFY2026 (Q1+Q2+Q3+Q4) vs FY2025 (Q1+Q2+Q3+Q4)
Revenue
$300M
↑+47.6% +$97Mvs FY2025 (Q1+Q2+Q3+Q4)
Gross Profit
$280M
↑+53.8% +$98Mvs FY2025 (Q1+Q2+Q3+Q4)
Operating profit
$125M
↑+233.0% +$87Mvs FY2025 (Q1+Q2+Q3+Q4)
Net profit
$119M
↑+326.1% +$91Mvs FY2025 (Q1+Q2+Q3+Q4)
Click a Metric or Sankey Node to View Historical Trends
Show Source Data (Audit Panel)
Reconciled values per the quarterly mode pipeline. Compare against SEC EDGAR filings.
Line itemFY2026 (Q1+Q2+Q3+Q4)FY2025 (Q1+Q2+Q3+Q4)
Revenue$300M$203M
COGS$20M$21M
Gross Profit$280M$182M
R&D$26M$26M
SG&A$119M$112M
D&A$2M$2M
Other OpEx$8M$4M
Operating Income$125M$37M
Interest Exp.$3M$9M
Other Non-Op$0$0
Pretax Income$122M$29M
Tax$3M$946K
Net Income$119M$28M

QuarterCharts · SEC EDGAR data · RIGL · Comparing FY2026 (Q1+Q2+Q3+Q4) vs FY2025 (Q1+Q2+Q3+Q4)